Stop Reading. Write This Down.
Teeka Tiwari picked Bitcoin at $428 before it became the first trillion-dollar coin by market value.

Now he’s giving away the name of his next top pick for FREE!
Click here and write its name down

TR Insider Trading (Trillium Therapeutics)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$3,451,138.42

Trillium Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Trillium Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Trillium Therapeutics Share Price & Price History

Current Price: C$0.00
Price Change: +0.30 (1.20%)
As of 03/16/2019 11:34 AM ET

This chart shows the closing price history over time for TR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
BIG — December 1st Crypto Prediction
According to Teeka Tiwari, voted the world’s #1 Most Trusted Crypto Expert by 130,000 analysts…

This could be your LAST CHANCE to capture the biggest potential crypto profits.
Click Here to Watch Now!

Trillium Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/7/2021Robert UgerSenior OfficerSell3,646C$11.88C$43,314.48
5/7/2021Robert UgerSenior OfficerSell3,646C$12.28C$44,758.30
4/8/2021Penka PetrovaSenior OfficerSell2,708C$14.64C$39,641.87
3/12/2021Robert UgerSenior OfficerSell2,917C$15.80C$46,089.77
2/8/2021Penka PetrovaSenior OfficerSell2,708C$16.70C$45,218.18
1/11/2021Penka PetrovaSenior OfficerSell508C$20.07C$10,197.41
1/8/2021James Todd ParsonsSenior OfficerSell8,505C$20.84C$177,237.70
12/31/2020James Todd ParsonsSenior OfficerSell4,250C$19.52C$82,943.85
12/18/2020James Todd ParsonsSenior OfficerSell65,104C$16.79C$1,092,881.58
12/16/2020James Todd ParsonsSenior OfficerSell14,162C$14.93C$211,446.02
12/14/2020James Todd ParsonsSenior OfficerSell106,908C$15.50C$1,657,409.26
See Full Table
Insider Trading at Trillium Therapeutics?
Sign-up to receive's daily insider buying and selling report for Trillium Therapeutics and related companies.

SEC Filings (Institutional Ownership Changes) for Trillium Therapeutics (TSE:TR)

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.
Read More on Trillium Therapeutics

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


49,075 shs

Average Volume

99,071 shs

Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Trillium Therapeutics?

Trillium Therapeutics' top insider investors include:
  1. James Todd Parsons (Senior Officer)
  2. Penka Petrova (Senior Officer)
  3. Robert Uger (Senior Officer)
Major Crypto Event — Days Away. Are You Prepared?
According to Teeka Tiwari, the man voted #1 Most Trusted Crypto Expert... We are quickly approaching what could be the most important event in crypto history.
Learn More.